Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Blocks Teva's Generic Lipitor In The U.K.

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer wins temporary injunction on Teva's U.K launch of generic atorvastatin; hearing scheduled for July.

You may also be interested in...



Pfizer Keeps Teva's Generic Lipitor Out Of U.K. For Now; Wins Six Month Patent Extension

Pfizer's block against Teva's generic Lipitor in the U.K. will remain in place until a full trial later this year; pharmacies caught between the warring factions.

Pfizer Keeps Teva's Generic Lipitor Out Of U.K. For Now; Wins Six Month Patent Extension

Pfizer's block against Teva's generic Lipitor in the U.K. will remain in place until a full trial later this year; pharmacies caught between the warring factions.

At-Risk Launches: Three Cases May Determine How Damages Are Calculated

How risky are at-risk launches of generic products?

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel